ArticleJournal of cardiovascular translational research2026
Deep Survival Modeling With Echocardiographic Myocardial Texture Radiomics for Prediction of Major Adverse Cardiovascular Events in Hypertrophic Cardiomyopathy.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hypertrophic cardiomyopathy (HCM) carries substantial risk of major adverse cardiovascular events (MACE), yet current tools do not fully exploit quantitative myocardial texture from routine echocardiography. We retrospectively studied 413 patients with HCM from two tertiary centers to develop and externally validate a deep survival model integrating transthoracic echocardiographic texture radiomics with clinical and conventional echocardiographic variables. Patients from one center (n = 308) were used for development and internal testing and those from the other (n = 105) for external validation. The best-performing model was selected by cross-validated Harrell C-index and interpreted using Shapley additive explanations. During median follow-up of 30.7 and 35.6 months, 83 patients (20.1%) experienced a first MACE. The Combined model showed the highest concordance and net clinical benefit, with age, RadScore, left atrial diameter, and maximal wall thickness as leading contributors. This model may provide an accessible approach to individualised MACE risk stratification in HCM.
Indexed as
Identifiers
42825975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.